# Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

Source: https://onco.cc/trials/nct00551525/  
OnCo record `nct00551525` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Samarium-153 lexidronam in Prostate cancer, run by Radiation Therapy Oncology Group, completed.

## Summary

Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer is a phase 2 interventional study registered as NCT00551525 by Radiation Therapy Oncology Group, with 67 participants recorded, started 2008-04 and reaching its primary completion in 2014-07. Interventions recorded: Radiotherapy, Samarium 153. Conditions recorded: Prostate Cancer.

Linked to the drug Samarium-153 lexidronam because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00551525
- Phase: 2
- Setting: A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy
- Sponsor: Radiation Therapy Oncology Group
- Enrolled: 67

## Sources

- ClinicalTrials.gov NCT00551525: https://clinicaltrials.gov/study/NCT00551525

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Samarium-153 lexidronam](https://onco.cc/drugs/samarium-153-lexidronam/)

---
JSON: https://onco.cc/api/v1/entities/nct00551525.json